RBC Capital Maintains Outperform on Sarepta Therapeutics, Raises Price Target to $157
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has maintained an Outperform rating on Sarepta Therapeutics (NASDAQ:SRPT) and increased the price target from $151 to $157.
February 29, 2024 | 5:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reaffirmed its Outperform rating on Sarepta Therapeutics and raised its price target from $151 to $157.
The increase in price target by a reputable analyst firm like RBC Capital typically signals a positive outlook on the company's future performance, potentially leading to increased investor confidence and a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100